A 20 mg vial reconstituted with bacteriostatic water yields about 10.0 mg/mL
Building on that success, offering access to compounded GLP-1s gives medical providers and customers consistent and affordable access to effective, trusted and safe medications
Documentation and tracking Keep a simple log for each vial: reconstitution date, water volume added, concentration, and a running tally of doses drawn with dates
Clinical Trial Evidence for Retatrutide The most widely referenced data comes from a Phase 2 trial published in the New England Journal of Medicine in 2023
Multiple access strategies exist beyond insurance coverage, and costs vary dramatically based on approach
Gastrointestinal symptoms affect roughly 15 to 25% of people at this dose, though most are milder than what they experienced during initial titration